Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin:: Implications for the inhibition of factor Xa, tPA, and urokinase

被引:97
作者
Renatus, M
Bode, W
Huber, R
Stürzebecher, J
Stubbs, MT
机构
[1] Univ Marburg, Inst Pharmazeut Chem, D-35032 Marburg, Germany
[2] Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany
[3] Klinikum Univ Jena, Zentrum Vaskulare Biol & Med, D-99089 Erfurt, Germany
关键词
D O I
10.1021/jm981068g
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The trypsin-like serine proteinase superfamily contains a number of potential therapeutic targets, many of which are unsuitable for routine X-ray crystallographic studies. We have cocrystallized a selection of benzamidine-based inhibitors with bovine trypsin and solved their structures to a resolution of up to 1.7 Angstrom. Despite similar chemical formulas, the inhibitors exhibit a range of diverse binding modes that reflect their inhibitory spectra against the serine proteinases trypsin, thrombin, factor Xa, tissue-type plasminogen activator (tPA) and urokinase (uPA). In contrast to the compact folded conformations of thrombin inhibitors which allow optimal binding in the well-defined hydrophobic S2/S4 pocket of thrombin, those effective against factor Xa exhibit an extended conformation that allows occupation of the S3/S4 region, where hydrophobic and electrostatic interactions can stabilize the conformation. One group of inhibitors containing an N-terminal 2,4,6-triisopropylphenylsulfonyl (TIPPS) moiety show little or no penetration into the S3/S4 subsites of trypsin. These latter sites are occluded in uPA, explaining why this class of compounds is effective against uPA. Despite presenting an extensive hydrophobic surface toward the solvent, the K-i values for TIPPS-containing compounds against trypsin is in the range 10(-7) to 10(-8) M. Comparison of the binding of a bis-benzamidine inhibitor in trypsin and tPA indicate that a shift, in potency can be induced by relatively minor changes in binding mode. Implications for the inhibition of these proteinases are discussed.
引用
收藏
页码:5445 / 5456
页数:12
相关论文
共 41 条
[21]   STRUCTURE OF HUMAN DES(1-45) FACTOR-XA AT 2.2-ANGSTROM RESOLUTION [J].
PADMANABHAN, K ;
PADMANABHAN, KP ;
TULINSKY, A ;
PARK, CH ;
BODE, W ;
HUBER, R ;
BLANKENSHIP, DT ;
CARDIN, AD ;
KISIEL, W .
JOURNAL OF MOLECULAR BIOLOGY, 1993, 232 (03) :947-966
[22]  
Rabbani SA, 1998, INT J ONCOL, V12, P911
[23]   Structural mapping of the active site specificity determinants of human tissue-type plasminogen activator - Implications for the design of low molecular weight substrates and inhibitors [J].
Renatus, M ;
Bode, W ;
Huber, R ;
Sturzebecher, J ;
Prasa, D ;
Fischer, S ;
Kohnert, U ;
Stubbs, MT .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (35) :21713-21719
[24]  
SCHROEDER DD, 1968, J BIOL CHEM, V243, P2943
[25]   (Z,Z)-2,7-bis(4-amidinobenzylidene)cycleheptan-1-one: Identification of a highly active inhibitor of blood coagulation factor Xa [J].
Shaw, KJ ;
Guilford, WJ ;
Dallas, JL ;
Koovakkaat, SK ;
McCarrick, MA ;
Liang, A ;
Light, DR ;
Morrissey, MM .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (19) :3551-3556
[26]   THE CRYSTAL-STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR [J].
SPRAGGON, G ;
PHILLIPS, C ;
NOWAK, UK ;
PONTING, CP ;
SAUNDERS, D ;
DOBSON, CM ;
STUART, DI ;
JONES, EY .
STRUCTURE, 1995, 3 (07) :681-691
[27]  
Stubbs MT, 1996, CURR PHARM DESIGN, V2, P543
[28]   CRYSTAL-STRUCTURES OF FACTOR XA SPECIFIC INHIBITORS IN COMPLEX WITH TRYPSIN - STRUCTURAL GROUNDS FOR INHIBITION OF FACTOR XA AND SELECTIVITY AGAINST THROMBIN [J].
STUBBS, MT ;
HUBER, R ;
BODE, W .
FEBS LETTERS, 1995, 375 (1-2) :103-107
[29]   The three-dimensional structure of recombinant leech-derived tryptase inhibitor in complex with trypsin - Implications for the structure of human mast cell tryptase and its inhibition [J].
Stubbs, MT ;
Morenweiser, R ;
Sturzebecher, J ;
Bauer, M ;
Bode, W ;
Huber, R ;
Piechottka, GP ;
Matschiner, G ;
Sommerhoff, CP ;
Fritz, H ;
Auerswald, EA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (32) :19931-19937
[30]  
STUBBS MT, 1993, PERSPECT DRUG DISCOV, V1, P431